4.8 Article

Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions

期刊

ONCOGENE
卷 40, 期 7, 页码 1284-1299

出版社

SPRINGERNATURE
DOI: 10.1038/s41388-020-01603-6

关键词

-

资金

  1. Ligue contre le cancer cd69, 2016
  2. Breast Cancer Research Foundation (BCRF, USA) [BCRF-16-096]
  3. Deutsche Forschungsgemeinschaft, SPP microBONE
  4. INSERM, University Claude Bernard Lyon 1
  5. Project LIA/LEA 2016 of the University of Lyon, within the program Investissements d'Avenir [ASC17018CSA, ANR-11-IDEX-0007]
  6. LabEX DEVweCAN of the University of Lyon, within the program Investissements d'Avenir [ANR-11-IDEX-0007, ANR-10-LABX-61]
  7. Inca [Transla09-112]

向作者/读者索取更多资源

This study identified ITGA5 as a mediator of breast-to-bone metastasis, with high expression correlating with poor bone metastasis-free survival. Silencing ITGA5 impaired tumor cell functions and bone metastasis, while inhibition with M200 showed similar effects.
Bone metastasis remains a major cause of mortality and morbidity in breast cancer. Therefore, there is an urgent need to better select high-risk patients in order to adapt patient's treatment and prevent bone recurrence. Here, we found that integrin alpha5 (ITGA5) was highly expressed in bone metastases, compared to lung, liver, or brain metastases. High ITGA5 expression in primary tumors correlated with the presence of disseminated tumor cells in bone marrow aspirates from early stage breast cancer patients (n = 268; p = 0.039). ITGA5 was also predictive of poor bone metastasis-free survival in two separate clinical data sets (n = 855, HR = 1.36, p = 0.018 and n = 427, HR = 1.62, p = 0.024). This prognostic value remained significant in multivariate analysis (p = 0.028). Experimentally, ITGA5 silencing impaired tumor cell adhesion to fibronectin, migration, and survival. ITGA5 silencing also reduced tumor cell colonization of the bone marrow and formation of osteolytic lesions in vivo. Conversely, ITGA5 overexpression promoted bone metastasis. Pharmacological inhibition of ITGA5 with humanized monoclonal antibody M200 (volociximab) recapitulated inhibitory effects of ITGA5 silencing on tumor cell functions in vitro and tumor cell colonization of the bone marrow in vivo. M200 also markedly reduced tumor outgrowth in experimental models of bone metastasis or tumorigenesis, and blunted cancer-associated bone destruction. ITGA5 was not only expressed by tumor cells but also osteoclasts. In this respect, M200 decreased human osteoclast-mediated bone resorption in vitro. Overall, this study identifies ITGA5 as a mediator of breast-to-bone metastasis and raises the possibility that volociximab/M200 could be repurposed for the treatment of ITGA5-positive breast cancer patients with bone metastases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据